| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NEK2 |
| Uniprot No | P51955 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-445aa |
| 氨基酸序列 | MPSRAEDYEV LYTIGTGSYG RCQKIRRKSD GKILVWKELD YGSMTEAEKQ MLVSEVNLLR ELKHPNIVRY YDRIIDRTNT TLYIVMEYCE GGDLASVITK GTKERQYLDE EFVLRVMTQL TLALKECHRR SDGGHTVLHR DLKPANVFLD GKQNVKLGDF GLARILNHDT SFAKTFVGTP YYMSPEQMNR MSYNEKSDIW SLGCLLYELC ALMPPFTAFS QKELAGKIRE GKFRRIPYRY SDELNEIITR MLNLKDYHRP SVEEILENPL IADLVADEQR RNLERRGRQL GEPEKSQDSS PVLSELKLKE IQLQERERAL KAREERLEQK EQELCVRERL AEDKLARAEN LLKNYSLLKE RKFLSLASNP ELLNLPSSVI KKKVHFSGES KENIMRSENS ESQLTSKSKC KDLKKRLHAA QLRAQALSDI EKNYQLKSRQ ILGMR |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NEK2重组蛋白的3-4篇参考文献示例(注：文献信息为示例，建议通过学术数据库核实具体内容)：
---
1. **文献名称**: *"NEK2 kinase as a therapeutic target in cancer: Structural and functional insights"*
**作者**: Fry, A.M., et al.
**摘要**: 该研究通过重组NEK2蛋白的体外实验，解析了其激酶结构域的关键功能位点，并验证了其在癌细胞有丝分裂中的调控作用，为靶向NEK2的抗癌药物设计提供了理论依据。
2. **文献名称**: *"Expression, purification, and enzymatic characterization of recombinant human NEK2"*
**作者**: Chen, Y., & Prigent, C.
**摘要**: 描述了利用大肠杆菌表达系统高效制备重组NEK2蛋白的方法，优化了纯化流程，并通过体外磷酸化实验证实其对底物(如C-Nap1)的催化活性及ATP依赖性。
3. **文献名称**: *"NEK2-dependent phosphorylation of Hec1 promotes centrosome disjunction"*
**作者**: Lou, Y., et al.
**摘要**: 利用重组NEK2蛋白进行体外激酶实验，揭示了NEK2通过磷酸化Hec1蛋白调控中心体分离的分子机制，强调了其在维持基因组稳定性中的关键作用。
4. **文献名称**: *"High-throughput screening identifies novel NEK2 inhibitors using recombinant kinase assays"*
**作者**: Huang, X., et al.
**摘要**: 基于重组NEK2蛋白的高通量筛选平台，发现了多个抑制NEK2激酶活性的小分子化合物，并验证了其诱导癌细胞有丝分裂停滞的效果。
---
**提示**：以上文献为示例，实际研究中建议通过PubMed或Web of Science以“NEK2 recombinant protein”“NEK2 kinase activity”等关键词检索最新研究。
NEK2 (NIMA-related kinase 2) is a serine/threonine kinase belonging to the NIMA family of kinases, which play critical roles in cell cycle regulation, particularly in mitotic progression. Structurally, NEK2 contains a conserved N-terminal catalytic kinase domain and a C-terminal regulatory region involved in substrate binding and autoregulation. It primarily localizes to centrosomes and is essential for centrosome maturation, spindle assembly, and chromosome alignment during mitosis. NEK2 activity peaks at the G2/M phase transition and is tightly regulated through phosphorylation, dimerization, and interactions with binding partners like PP1 phosphatase.
Overexpression or dysregulation of NEK2 is strongly linked to cancer progression. Elevated NEK2 levels are observed in various malignancies, including breast, ovarian, and prostate cancers, where it promotes genomic instability, drug resistance, and epithelial-mesenchymal transition by targeting substrates such as C-Nap1. Hec1. and β-catenin. Its dual role in both cell cycle control and non-mitotic processes (e.g., DNA repair, ciliogenesis) makes it a compelling therapeutic target.
Recombinant NEK2 proteins are typically produced in Escherichia coli or mammalian expression systems to preserve post-translational modifications. These engineered proteins often include affinity tags (e.g., His-tag, GST-tag) for purification and are widely used in kinase activity assays, structural studies, and inhibitor screening. Researchers utilize NEK2 recombinant proteins to investigate its biochemical properties, substrate specificity, and interactions with potential anticancer compounds. Current drug development efforts focus on designing small-molecule inhibitors that selectively block NEK2 kinase activity while minimizing off-target effects, aiming to exploit its cancer-associated functions for therapeutic intervention.
×
